CR20160502A - Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso - Google Patents

Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso

Info

Publication number
CR20160502A
CR20160502A CR20160502A CR20160502A CR20160502A CR 20160502 A CR20160502 A CR 20160502A CR 20160502 A CR20160502 A CR 20160502A CR 20160502 A CR20160502 A CR 20160502A CR 20160502 A CR20160502 A CR 20160502A
Authority
CR
Costa Rica
Prior art keywords
virus
antibodies against
methods
influenza
hemaglutinine
Prior art date
Application number
CR20160502A
Other languages
English (en)
Inventor
Henry Chiu
Hyunjoo Park
Ning Chai
Lee Swem
Zhonghua Lin
Gerald R Nakamura
Nancy Chiang
Min Xu
Mercedesz Balazs
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CR20160502A publication Critical patent/CR20160502A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos de hemaglutinina contra el virus de la influenza B, composiciones que comprenden anticuerpos de hemaglutinina contra el virus de la influenza B y sus métodos de uso.
CR20160502A 2014-03-27 2015-03-26 Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso CR20160502A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461971123P 2014-03-27 2014-03-27
PCT/US2015/022758 WO2015148806A1 (en) 2014-03-27 2015-03-26 Anti-influenza b virus hemagglutinin antibodies and methods of use

Publications (1)

Publication Number Publication Date
CR20160502A true CR20160502A (es) 2017-02-03

Family

ID=52829396

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160502A CR20160502A (es) 2014-03-27 2015-03-26 Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso

Country Status (20)

Country Link
US (2) US9745365B2 (es)
EP (1) EP3122771A1 (es)
JP (1) JP2017512471A (es)
KR (1) KR20160135830A (es)
CN (1) CN106132987A (es)
AR (1) AR099855A1 (es)
AU (1) AU2015235983A1 (es)
BR (1) BR112016022113A2 (es)
CA (1) CA2942820A1 (es)
CL (2) CL2016002413A1 (es)
CR (1) CR20160502A (es)
EA (1) EA201691945A1 (es)
IL (1) IL247870A0 (es)
MA (1) MA39803A (es)
MX (1) MX2016012530A (es)
PE (1) PE20161376A1 (es)
PH (1) PH12016501873A1 (es)
SG (1) SG11201607945UA (es)
TW (1) TW201620932A (es)
WO (1) WO2015148806A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018073133A2 (pt) 2016-05-10 2019-04-30 Genentech Inc métodos de diminuição das ligações trissulfeto durante a produção recombinante de polipeptídeos
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
JP2021519073A (ja) 2018-03-29 2021-08-10 ジェネンテック， インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
EP3980544A1 (en) 2018-12-21 2022-04-13 F. Hoffmann-La Roche AG Targeted integration of nucleic acids
RU2714246C1 (ru) * 2018-12-28 2020-02-13 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам вируса гриппа в
JP7611908B2 (ja) * 2019-10-28 2025-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗血球凝集素抗体およびその使用方法
MX2022008901A (es) * 2020-01-24 2022-08-16 Regeneron Pharma Conjugados de proteinas-compuestos antivirales.
US12098365B2 (en) 2020-03-26 2024-09-24 Genentech, Inc. Modified mammalian cells
KR20230027043A (ko) 2020-06-24 2023-02-27 제넨테크, 인크. 핵산의 표적화 통합
EP4172192A1 (en) 2020-06-24 2023-05-03 Genentech, Inc. Apoptosis resistant cell lines
JP2023539201A (ja) 2020-08-28 2023-09-13 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
CN114316032B (zh) * 2020-09-27 2022-12-27 东莞市朋志生物科技有限公司 抗乙型流感病毒的抗体、检测乙型流感病毒的试剂和试剂盒
JP2024514222A (ja) 2021-04-19 2024-03-28 ジェネンテック， インコーポレイテッド 改変された哺乳動物細胞
CN117396599A (zh) 2021-05-21 2024-01-12 基因泰克公司 用于生产目的重组产物的经修饰的细胞
US20260183380A1 (en) 2022-11-14 2026-07-02 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
WO2024107879A1 (en) 2022-11-15 2024-05-23 Genentech, Inc. Combined transposon-mediated integration and targeted integration of nucleic acids into host cells
JP2026502534A (ja) 2023-01-12 2026-01-23 ジェネンテック， インコーポレイテッド 核酸の標的組込みのためのコンビナトリアルベクターのクローニングおよびトランスフェクション戦略
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12649790B2 (en) 2023-07-03 2026-06-09 Medicovestor, Inc. Proteins that bind SP17 including fully-human anti-SP17 antibodies
US12624097B2 (en) 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12673991B2 (en) 2023-12-26 2026-07-07 Medicovestor, Inc. Methods of crosslinking IgG
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
BE1018561A3 (fr) 2008-12-24 2011-03-01 Galactic Sa Procede de purification de l'acide lactique par cristallisation.
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
EP2731967B1 (en) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
JP6170507B2 (ja) * 2012-01-31 2017-07-26 国立大学法人大阪大学 Ｂ型インフルエンザウイルスに対する広範な保護を与えるヒトモノクローナル抗体及びその使用方法
MX360056B (es) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.

Also Published As

Publication number Publication date
MX2016012530A (es) 2017-01-05
AR099855A1 (es) 2016-08-24
CL2018002874A1 (es) 2018-12-14
PH12016501873A1 (en) 2017-01-09
WO2015148806A1 (en) 2015-10-01
CN106132987A (zh) 2016-11-16
MA39803A (fr) 2017-02-01
US20170320937A1 (en) 2017-11-09
EP3122771A1 (en) 2017-02-01
AU2015235983A1 (en) 2016-10-06
EA201691945A1 (ru) 2017-02-28
US9745365B2 (en) 2017-08-29
CA2942820A1 (en) 2015-10-01
TW201620932A (zh) 2016-06-16
JP2017512471A (ja) 2017-05-25
IL247870A0 (en) 2016-11-30
BR112016022113A2 (pt) 2017-10-31
US20150274812A1 (en) 2015-10-01
KR20160135830A (ko) 2016-11-28
SG11201607945UA (en) 2016-10-28
PE20161376A1 (es) 2016-12-26
CL2016002413A1 (es) 2017-06-23

Similar Documents

Publication Publication Date Title
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
EP3538146A4 (en) INFLUENZA VACCINE
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
MX2017000395A (es) Vacunas contra virus influenza y usos de las mismas.
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
MX2018003491A (es) Represores de htt y usos de estos.
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
MX2015016755A (es) Reagrupamiento del virus de influenza.
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2018000634A (es) Nueva especie de tobamovirus.
BR112017002090A2 (pt) formulação de fator viii
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.